12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pixantrone: Additional Phase III data

Additional data from the open-label, international Phase III EXTEND (PIX301) trial in 140 patients with advanced, relapsed, aggressive NHL showed that pixantrone produced a response lasting >=4 months in 25.7% of patients compared to 8.6% of patients receiving standard chemotherapy (p=0.012). Preliminary...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >